Eduardo J Folco1, Galina K Sukhova1, Thibaut Quillard1, Peter Libby2. 1. From the Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. 2. From the Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. plibby@partners.org.
Abstract
RATIONALE: Inflammation drives atherogenesis. Animal and human studies have implicated interleukin-1β (IL-1β) in this disease. Moderate hypoxia, a condition that prevails in the atherosclerotic plaque, may conspire with inflammation and contribute to the evolution and complications of atherosclerosis through mechanisms that remain incompletely understood. OBJECTIVE: This study investigated the links between hypoxia and inflammation by testing the hypothesis that moderate hypoxia modulates IL-1β production in activated human macrophages. METHODS AND RESULTS: Our results demonstrated that hypoxia enhances pro-IL-1β protein, but not mRNA, expression in lipopolysaccharide-stimulated human macrophages. We show that hypoxia limits the selective targeting of pro-IL-1β to autophagic degradation, thus prolonging its half-life and promoting its intracellular accumulation. Furthermore, hypoxia increased the expression of NLRP3, a limiting factor in NLRP3 inflammasome function, and augmented caspase-1 activation in lipopolysaccharide-primed macrophages. Consequently, hypoxic human macrophages secreted higher amounts of mature IL-1β than did normoxic macrophages after treatment with crystalline cholesterol, an endogenous danger signal that contributes to atherogenesis. In human atherosclerotic plaques, IL-1β localizes predominantly to macrophage-rich regions that express activated caspase-1 and the hypoxia markers hypoxia-inducible factor 1α and hexokinase-2, as assessed by immunohistochemical staining of carotid endarterectomy specimens. CONCLUSIONS: These results indicate that hypoxia potentiates IL-1β expression in cultured human macrophages and in the context of atheromata, therefore unveiling a novel proinflammatory mechanism that may participate in atherogenesis.
RATIONALE: Inflammation drives atherogenesis. Animal and human studies have implicated interleukin-1β (IL-1β) in this disease. Moderate hypoxia, a condition that prevails in the atherosclerotic plaque, may conspire with inflammation and contribute to the evolution and complications of atherosclerosis through mechanisms that remain incompletely understood. OBJECTIVE: This study investigated the links between hypoxia and inflammation by testing the hypothesis that moderate hypoxia modulates IL-1β production in activated human macrophages. METHODS AND RESULTS: Our results demonstrated that hypoxia enhances pro-IL-1β protein, but not mRNA, expression in lipopolysaccharide-stimulated human macrophages. We show that hypoxia limits the selective targeting of pro-IL-1β to autophagic degradation, thus prolonging its half-life and promoting its intracellular accumulation. Furthermore, hypoxia increased the expression of NLRP3, a limiting factor in NLRP3 inflammasome function, and augmented caspase-1 activation in lipopolysaccharide-primed macrophages. Consequently, hypoxic human macrophages secreted higher amounts of mature IL-1β than did normoxic macrophages after treatment with crystalline cholesterol, an endogenous danger signal that contributes to atherogenesis. In humanatherosclerotic plaques, IL-1β localizes predominantly to macrophage-rich regions that express activated caspase-1 and the hypoxia markers hypoxia-inducible factor 1α and hexokinase-2, as assessed by immunohistochemical staining of carotid endarterectomy specimens. CONCLUSIONS: These results indicate that hypoxia potentiates IL-1β expression in cultured human macrophages and in the context of atheromata, therefore unveiling a novel proinflammatory mechanism that may participate in atherogenesis.
Authors: Janet Chamberlain; David Evans; Andrea King; Rachael Dewberry; Steven Dower; David Crossman; Sheila Francis Journal: Am J Pathol Date: 2006-04 Impact factor: 4.307
Authors: Sanjeev Mariathasan; David S Weiss; Kim Newton; Jacqueline McBride; Karen O'Rourke; Meron Roose-Girma; Wyne P Lee; Yvette Weinrauch; Denise M Monack; Vishva M Dixit Journal: Nature Date: 2006-01-11 Impact factor: 49.962
Authors: Pontus Boström; Björn Magnusson; Per-Arne Svensson; Olov Wiklund; Jan Borén; Lena M S Carlsson; Marcus Ståhlman; Sven-Olof Olofsson; Lillemor Mattsson Hultén Journal: Arterioscler Thromb Vasc Biol Date: 2006-06-01 Impact factor: 8.311
Authors: Faten Merhi-Soussi; Brenda R Kwak; David Magne; Christos Chadjichristos; Marina Berti; Graziano Pelli; Richard W James; François Mach; Cem Gabay Journal: Cardiovasc Res Date: 2005-06-01 Impact factor: 10.787
Authors: Judith C Sluimer; Jean-Marie Gasc; Job L van Wanroij; Natasja Kisters; Mathijs Groeneweg; Maarten D Sollewijn Gelpke; Jack P Cleutjens; Luc H van den Akker; Pierre Corvol; Bradly G Wouters; Mat J Daemen; Ann-Pascale J Bijnens Journal: J Am Coll Cardiol Date: 2008-04-01 Impact factor: 24.094
Authors: S H Venkatesha; S Dudics; E Weingartner; E C So; Jhf Pedra; K D Moudgil Journal: Int J Immunopathol Pharmacol Date: 2015-07-30 Impact factor: 3.219